Skip to main navigation

About
- Team
- Contact
Research & Development
Pipeline
- RMC-4630
- Mutant RAS
- SOS1
- RMC-5552
Investors
Careers

Press Releases

Press Releases

Year

March 20, 2017

REVOLUTION Medicines Appoints Cancer Leader Dr. Stephen Kelsey as President of Research and Development

December 20, 2016

REVOLUTION Medicines Raises Additional $25 Million in Series A Financing

December 13, 2016

REVOLUTION Medicines Names Distinguished Cancer Scientists and Drug Hunters to Senior Advisory Roles

June 14, 2016

REVOLUTION Medicines Names Academic Co-Founder, Michael Fischbach, Ph.D., and Senior Advisor, Eric Gordon, Ph.D.

September 30, 2015

FierceBiotech Names Revolution Medicines as a “Fierce 15” Biotech Company of 2015

June 1, 2015

Rationally Designed Antifungal Compounds that Evade Resistance Reported in Nature Chemical Biology by Scientific Founder of REVOLUTION Medicines

April 9, 2015

REVOLUTION Medicines Appoints Pharmaceutical Commercial Executive Elizabeth McKee Anderson to Board of Directors

March 12, 2015

Major Advances in Synthetic Chemistry Reported in Science by Founding Scientist of REVOLUTION Medicines

March 5, 2015

REVOLUTION Medicines Expands Executive Leadership Team

February 4, 2015

Third Rock Ventures Launches REVOLUTION Medicines with $45 Million Series A to Redesign Evolution’s Products to Treat Serious Diseases

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Current page 4

Displaying 31 - 40 of 40

Email Alerts

RSS Feeds

Print Page

Contact IR

© 2020 Revolution Medicines, Inc. | 700 Saginaw Drive | Redwood City, CA 94063

Search Investor Relations